SOUTH SAN FRANCISCO, Calif.
Dec. 7, 2011
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that
, the company's president and chief operating officer, is scheduled to present a company overview at the Oppenheimer 22nd Annual Healthcare Conference in
New York City
Wednesday, December 14th
1:00 p.m. ET
To access the live audio webcast of the company presentation or the subsequent archived recording, log on to
. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.
About Rigel ( www.rigel.com)
Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include fostamatinib, an oral syk inhibitor that has started its Phase 3 clinical trial program for rheumatoid arthritis, and R343, an inhaled syk inhibitor that has completed Phase 1 clinical trials for asthma.
SOURCE Rigel Pharmaceuticals, Inc.